TCGA-D8-A1Y2-01A-11R-A157-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 14
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.570
- INFLAMMATORY_RESPONSE+0.570
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- INTERFERON_GAMMA_RESPONSE+0.550
- IL6_JAK_STAT3_SIGNALING+0.530
- COMPLEMENT+0.490
- INTERFERON_ALPHA_RESPONSE+0.490
- COAGULATION+0.430
- TNFA_SIGNALING_VIA_NFKB+0.420
- KRAS_SIGNALING_UP+0.380
Top 10 suppressed
- MITOTIC_SPINDLE-0.360
- G2M_CHECKPOINT-0.320
- WNT_BETA_CATENIN_SIGNALING-0.310
- E2F_TARGETS-0.230
- HEDGEHOG_SIGNALING-0.230
- ESTROGEN_RESPONSE_EARLY-0.190
- NOTCH_SIGNALING-0.100
- ESTROGEN_RESPONSE_LATE-0.080
- SPERMATOGENESIS-0.020
- KRAS_SIGNALING_DN+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-35-4122-01A-01R-1107-07 | — | cohortA1 | 0.909 |
| 2 | MDT-AP-2377 | Med | Medulloblastoma | 0.899 |
| 3 | 6f043250-acea-4315-8400-a172214c84c7 | — | — | 0.893 |
| 4 | TCGA-C8-A26X-01A-31R-A16F-07 | — | C | 0.884 |
| 5 | MDT-AP-0410 | Med | Medulloblastoma | 0.877 |
| 6 | TCGA-75-5126-01A-01R-1755-07 | — | cohortA1 | 0.874 |
| 7 | TCGA-35-4123-01A-01R-1107-07 | — | cohortA1 | 0.873 |
| 8 | 6815eba1-06e5-46d6-ad4b-e4132b5d1638 | — | — | 0.872 |
| 9 | 551ADCCD-D116-43D8-AABC-E7E111D79E70 | — | — | 0.871 |
| 10 | TCGA-38-4629-01A-02R-1206-07 | — | cohortA1 | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.570 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.570 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.550 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.530 | Inavolisib | — uncovered |
| COMPLEMENT | 0.490 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.420 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.310 | Idelalisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |